Severe Health‐Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient‐Reported Outcomes: Data From a Large Therapeutic Trial

Cornec, Divi; Devauchelle‐Pensec, Valérie; Mariette, Xavier; Jousse‐Joulin, Sandrine; Berthelot, Jean‐Marie; Perdriger, Aleth; Puéchal, Xavier; Guern, Véronique Le; Sibilia, Jean; Gottenberg, Jacques-Éric; Chiche, Laurent; Hachulla, É.; Hatron, P.Y.; Goëb, Vincent; Hayem, Gilles; Morel, Jacques; Zarnitsky, Charles; Dubost, Jean Jacques; Saliou, Philippe; Pers, Jacques Olivier; Séror, Raphaèle; Saraux, Alain

doi:10.1002/acr.22974

Cited by 77 publications

(65 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the TEARS and TRACTISS trials did not observe a significant effect of rituximab treatment on SF-36 scores, compared with placebo. This is consistent with findings that subjective symptoms improved only slightly (TEARS) or not at all (TRACTISS) in the rituximab group, as subjective symptoms are strong predictors of health-related qualityof-life in pSS patients [53].…”

Section: Effects On Quality Of Lifesupporting

confidence: 91%

The value of rituximab treatment in primary Sjögren's syndrome

Verstappen

Nimwegen

Vissink

et al. 2017

Clinical Immunology

View full text Add to dashboard Cite

Section: Effects On Quality Of Lifesupporting

confidence: 91%

The value of rituximab treatment in primary Sjögren's syndrome

Verstappen

Nimwegen

Vissink

et al. 2017

Clinical Immunology

View full text Add to dashboard Cite

“…Cardinal symptoms include mouth and eye dryness, marked fatigue and wide-spread pain, which have a profound effect on the quality of life of patients with pSS 2 . These symptoms are non-specific and can occur with many other conditions 3, 4 .…”

Section: Introductionmentioning

confidence: 99%

Incidence and Mortality of Physician-Diagnosed Primary Sjögren Syndrome

Gabriel

Crowson

Matteson

et al. 2017

Mayo Clinic Proceedings

Self Cite

View full text Add to dashboard Cite

Objective To estimate the incidence and mortality rates of physician-diagnosed primary Sjögren’s syndrome (pSS) among residents of Olmsted County, Minnesota, and their evolution over time. Patients and Methods All medical records of patients with a diagnosis or suspicion of SS in Olmsted County, MN, from January 1, 2006 to December 31, 2015 were reviewed to identify incident cases of pSS (defined according to physician diagnosis). These cases were combined with a previous 1976–2005 incident cohort from the same population. Incidence rates were age and sex adjusted to the US white 2010 population. Survival rates were compared with the expected rates in the population of Minnesota. Results With 61 incident cases of pSS diagnosed in Olmsted County in 2006–2015, the total cohort included 172 patients with incident pSS in 1976–2015. Of the 172 patients, 151 (88%) were women and 161 (94%) were white, with a mean (SD) age at diagnosis of 58.3 (16.7) years. The average age- and sex- adjusted annual incidence for 2006–2015 was 5.9 per 100,000 population (95%CI 4.4–7.4), and overall incidence for the entire period was 5.8 (95% CI: 4.9–6.6) per 100,000. The incidence increased with calendar time over the 40-year period (P=.005). There was no difference in mortality in the pSS cohort compared to expected (standardized mortality ratio 1.15, 95%CI 0.86–1.50). Conclusions The average annual incidence of pSS in this population based-cohort was 5.8/100,000, with a progressive increase over the 40 years covered by the study. Overall survival of pSS patients was not different from the general population.

show abstract

“…Cornec et al. () correlated quality of life measures as determined by the Short Form 36 (SF‐36) with ratings of SS disease activity. They found that patient ESSPRI ratings, measuring subjective symptoms, were strongly correlated with SF‐36, with significant correlations between ESSPRI rating and each individual domain of the SF‐36.…”

Section: Resultsmentioning

confidence: 99%

World Workshop on Oral Medicine VII: Immunobiologics for salivary gland disease in Sjögren's syndrome: A systematic review

et al. 2019

View full text Add to dashboard Cite

Objective This systematic review evaluated the efficacy of immunobiologics for the management of oral disease in Sjögren's syndrome (SS). Materials and Methods MEDLINE®, Embase, Scopus, and the Cochrane Library were searched for evidence on the use of immunobiologics for management of glandular disease in SS. Primary outcomes were xerostomia and salivary gland dysfunction, assessed via visual analogue scales, disease‐specific scales for SS, measurement of salivary flow, ultrasound data, and quality of life measures. Results Seventeen studies (11 randomized controlled trials and 6 observational studies) met inclusion criteria. Rituximab showed efficacy in improving salivary gland function but not xerostomia. Abatacept showed promise in improving both xerostomia and salivary flow. Belimumab exhibited long‐term improvement of salivary flow and subjective measures. The novel agent CFZ533 improved both disease activity and patient‐reported indexes. Conclusions There is strong evidence pointing to the efficacy of rituximab in the management of oral disease in SS. Future controlled trials may elucidate the efficacy of belimumab and abatacept. The new drug CFZ533 is a promising alternative for the management of SS and its salivary gland involvement. In considering these agents, the promise of efficacy must be balanced against the harmful effects associated with biologic agents.

show abstract

Severe Health‐Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient‐Reported Outcomes: Data From a Large Therapeutic Trial

Cited by 77 publications

References 30 publications

The value of rituximab treatment in primary Sjögren's syndrome

The value of rituximab treatment in primary Sjögren's syndrome

Incidence and Mortality of Physician-Diagnosed Primary Sjögren Syndrome

World Workshop on Oral Medicine VII: Immunobiologics for salivary gland disease in Sjögren's syndrome: A systematic review

Contact Info

Product

Resources

About